Centrient Pharmaceuticals
Manufacturer of foundational medicines (APIs and finished dosage forms) with emphasis on sustainable, quality-driven and secure supply. Operates an accredited multi-site global manufacturing and sales network, produces intermediates, APIs and made-to-order finished dosage forms, and highlights enzymatic/fermentation-based biotechnology, regulatory dossier support and environmental stewardship including antimicrobial-resistance (AMR) mitigation. Holds more than 500 local marketing authorisations and approximately 100 API dossiers (including DMFs/CEPs).
Industries
N/A
Nr. of Employees
medium (51-250)
Centrient Pharmaceuticals
Patents
Products
Active pharmaceutical ingredients (APIs) and intermediates
APIs and intermediates produced for antibiotics, statins and antifungals intended for downstream formulation or sale to pharmaceutical partners. Portfolio includes foundational medicines such as penicillin G, nystatin, statins, cephalosporins and amoxicillin.
Finished dosage forms (FDFs)
Made-to-order tablets, capsules and other FDFs manufactured to customer specifications.
Active pharmaceutical ingredients (APIs) and intermediates
APIs and intermediates produced for antibiotics, statins and antifungals intended for downstream formulation or sale to pharmaceutical partners. Portfolio includes foundational medicines such as penicillin G, nystatin, statins, cephalosporins and amoxicillin.
Finished dosage forms (FDFs)
Made-to-order tablets, capsules and other FDFs manufactured to customer specifications.
Services
Manufacture of intermediates, active pharmaceutical ingredients and made-to-order finished dosage forms at accredited global sites for pharmaceutical customers.
Preparation and maintenance of regulatory dossiers (CTD, DMF, CEP) to obtain marketing authorisations and support global registrations.
Implementation of wastewater technologies and analytical monitoring to reduce antibiotic residues and comply with industry PNEC targets.
Manufacture of intermediates, active pharmaceutical ingredients and made-to-order finished dosage forms at accredited global sites for pharmaceutical customers.
Preparation and maintenance of regulatory dossiers (CTD, DMF, CEP) to obtain marketing authorisations and support global registrations.
Implementation of wastewater technologies and analytical monitoring to reduce antibiotic residues and comply with industry PNEC targets.
Expertise Areas
- API and intermediate manufacturing for foundational medicines
- Finished dosage form (FDF) formulation and production
- Enzymatic and fermentation-based process development
- Pharmaceutical regulatory affairs and dossier management
Key Technologies
- Enzymatic biocatalysis for API synthesis
- Fermentation-based antibiotic production
- Wastewater treatment technologies for pharmaceutical effluent
- Low-ppb antibiotic residue detection assays
News & Updates
Blog by the company CEO on the importance of local antibiotic production and supply security in Europe.
Received Gold sustainability rating from EcoVadis for 2024.
Announced 100% compliance (for company sites and suppliers) with Predicted No-Effect Concentration (PNEC) discharge targets for oral antibiotics in 2022.
Opened an innovation laboratory to accelerate product and process development.
Blog by the company CEO on the importance of local antibiotic production and supply security in Europe.
Received Gold sustainability rating from EcoVadis for 2024.
Announced 100% compliance (for company sites and suppliers) with Predicted No-Effect Concentration (PNEC) discharge targets for oral antibiotics in 2022.
Opened an innovation laboratory to accelerate product and process development.